Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Devonian Health Group Inc V.GSD

Alternate Symbol(s):  DVHGF

Healthcare Biotechnology
Devonian Health Group Inc. is a clinical-stage pharmaceutical company. It specializes in the development of drugs for various autoimmune inflammatory conditions with novel therapeutic approaches to targeting unmet medical needs. It is developing prescription drugs for the treatment of inflammatory autoimmune diseases, including but not limited to, ulcerative colitis and atopic dermatitis. It is... see more

Recent & Breaking News (TSXV:GSD)

Devonian Health Group Inc. announces its participation to the ThinkEquity Conference in New York and closing of a Non-Brokered Private Placement of Units

Canada NewsWire October 22, 2025

Devonian Provides Corporate Update and Additional Information Regarding its Previously Announced Private Placement

Business Wire August 22, 2025

Devonian Announces Closing of a Private Placement of Units

Business Wire August 7, 2025

Devonian Health Group Reports Third Quarter 2025 Financial Results

Business Wire June 26, 2025

Devonian Appoints New Officers and Announces Grant of Stock Options

Business Wire June 9, 2025

Canadian Investment Regulatory Organization Trade Resumption - GSD

Canada NewsWire April 29, 2025

Devonian Health Group Announces Reinstatement of Quotation on the TSXV

Business Wire April 28, 2025

Devonian Health Group Reports Second Quarter 2025 Financial Results

Business Wire April 15, 2025

Devonian Health Group Reports Cease Trade Order

Business Wire April 14, 2025

Canadian Investment Regulatory Organization Trading Halt - GSD

Canada NewsWire April 8, 2025

Devonian Reports Delay of Financial Reporting

Business Wire April 1, 2025

Devonian Reports Results of its Annual General and Special Meeting of Shareholders

Business Wire March 24, 2025

Devonian Announces the Filing of a New Patent Application Relating to the Use of Thykamine(TM) as an Antifibrotic Agent

Business Wire February 19, 2025

Devonian Announces Positive in Vivo Results of Thykamine(TM) on Gene Expression Associated With Fibrosis

Business Wire February 18, 2025

Devonian Announces the Filing of a New Provisional Patent Application Relating to the Use of Thykamine(TM) for Treating Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Business Wire February 13, 2025

Devonian Reports Positive Results in MASH Liver Study

Business Wire February 13, 2025

Devonian Reports Distribution Agreement Termination

Business Wire February 7, 2025

Devonian Health Group Inc. Reports Superior Anti-Inflammatory Potency of Thykamine(TM) in Comparative In Vitro Study

Business Wire February 4, 2025

Devonian Appoints Viktoria Krasteva as Chief Financial Officer

Business Wire January 21, 2025

Devonian Health Group Reports First Quarter 2025 Financial Results and Grants Stock Options

Business Wire December 23, 2024